Scott Williams

Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial.

Rafael E de Feria Cardet, Michael S Hofman, Tatiana Segard, Jackie Yim, Scott Williams, Roslyn J Francis, Mark Frydenberg, Nathan Lawrentschuk, Declan G Murphy, Richard De Abreu Lourenco

Journal article  |  2020  |  European Urology

BACKGROUND: Before integrating prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)..

Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy.

Nattakorn Dhiantravan, John Violet, Renu Eapen, Omar Alghazo, Mark Scalzo, Price Jackson, Simon P Keam, Catherine Mitchell, Paul J Neeson, Shahneen Sandhu, Scott G Williams, Daniel Moon, Nathan Lawrentschuk, Arun Azad, Michael S Hofman, Declan G Murphy

Journal article  |  2020  |  European Urology Focus

LuTectomy is an open-label phase 1/2 nonrandomised clinical trial evaluating the dosimetry, efficacy, and toxicity of the lutetium..

ProPSMA Study: A prospective randomised multi-centre study of PSMA-PET/CT imaging for staging high risk prostate cancer prior to curative-intent surgery or radiotherapy

Nathan Lawrentschuk, Roslyn Francis, Colin Tang, Ian Vela, Paul Thomas, Natalie Rutherford, Jarad M Martin, Mark Frydenberg, Shakher Ramdave, LihMing Wong, Kim Taubman, SzeTing Lee, Edward Hsiao, Michelle Nottage, Ian Kirkwood, Emma Link, Alan Herschtal, Petra Marusic, Anetta Matera, Amir Iravani, et al.

Conference Proceedings  |  2020  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Andrew Kneebone, Carol Fraser-Browne, Gillian M Duchesne, Richard Fisher, Mark Frydenberg, Alan Herschtal, Scott G Williams, Chris Brown, Warick Delprado, Annette Haworth, David J Joseph, Jarad M Martin, John HL Matthews, Jeremy L Millar, Mark Sidhom, Nigel Spry, Colin I Tang, Sandra Turner, Kirsty L Wiltshire, Henry H Woo, et al.

Journal article  |  2020  |  The Lancet Oncology

Background: Adjuvant radiotherapy has been shown to halve the risk of biochemical progression for patients with high-risk disease ..

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation

Wanling Xie, Meredith M Regan, Marc Buyse, Susan Halabi, Philip W Kantoff, Oliver Sartor, Howard Soule, Donald Berry, Noel Clarke, Laurence Collette, Anthony D'Amico, Richard De Abreu Lourenco, James Dignam, Mario Eisenberger, Nicholas James, Karim Fizazi, Silke Gillessen, Yohann Loriot, Nicolas Mottet, Wendy Parulekar, et al.

Journal article  |  2020  |  Journal of Clinical Oncology

PURPOSE: Recently, we have shown that metastasis-free survival is a strong surrogate for overall survival (OS) in men with interme..

Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617

Justin Ferdinandus, John Violet, Shahneen Sandhu, Rodney J Hicks, Aravind S Ravi Kumar, Amir Iravani, Grace Kong, Tim Akhurst, Sue Ping Thang, Declan G Murphy, Scott Williams, Michael S Hofman

Journal article  |  2020  |  European Journal of Nuclear Medicine and Molecular Imaging

PURPOSE: We analysed quantitative biomarkers derived from both baseline whole-body imaging and blood serum to identify prognostic ..

Voxel-level biological optimisation of prostate IMRT using patient-specific tumour location and clonogen density derived from mpMRI

EJ Her, A Haworth, HM Reynolds, Y Sun, A Kennedy, V Panettieri, M Bangert, S Williams, MA Ebert

Journal article  |  2020  |  Radiation Oncology

Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of Lu-177-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer

John Violet, Shahneen Sandhu, Amir Iravani, Justin Ferdinandus, Thang Sue-Ping, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, David Pattison, Alexis Beaulieu, Jennifer Mooi, Ben Tran, Christina Guo, Victor Kalff, Declan G Murphy, Price Jackson, Peter Eu, Mark Scalzo, Scott G Williams, Rod J Hicks, et al.

Journal article  |  2020  |  Journal of Nuclear Medicine

177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen (PSMA), enabling targeted β-irradiation ..

Standard versus hypofractionated intensity-modulated radiotherapy for prostate cancer: assessing the impact on dose modulation and normal tissue effects when using patient-specific cancer biology.

Emily Jungmin Her, Martin Andrew Ebert, Angel M Kennedy, Hayley M Reynolds, Yu Sun, Scott Williams, Annette Haworth

Journal article  |  2020  |  Physics in Medicine & Biology

Hypofractionation of prostate cancer radiotherapy achieves tumour control at lower total radiation doses, however, increased recta..

P53: A Guardian of Immunity Becomes Its Saboteur through Mutation

Arjelle Decasa Agupitan, Paul Neeson, Scott Williams, Jason Howitt, Sue Haupt, Ygal Haupt

Journal article  |  2020  |  International Journal of Molecular Sciences

Awareness of the importance of immunity in controlling cancer development triggered research into the impact of its key oncogenic ..